These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 22805320)

  • 21. High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.
    Siesing C; Sorbye H; Dragomir A; Pfeiffer P; Qvortrup C; Pontén F; Jirström K; Glimelius B; Eberhard J
    PLoS One; 2017; 12(8):e0182512. PubMed ID: 28800641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis.
    Li J; Cheng Y; Tai D; Martinka M; Welch DR; Li G
    Oncogene; 2011 Feb; 30(8):896-906. PubMed ID: 20935672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer.
    Hua X; Yu L; Pan W; Huang X; Liao Z; Xian Q; Fang L; Shen H
    Diagn Pathol; 2012 Sep; 7():127. PubMed ID: 23006319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
    Jögi A; Brennan DJ; Rydén L; Magnusson K; Fernö M; Stål O; Borgquist S; Uhlen M; Landberg G; Påhlman S; Pontén F; Jirström K
    Mod Pathol; 2009 Dec; 22(12):1564-74. PubMed ID: 19734850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non-small cell lung cancer.
    Salomonsson A; Micke P; Mattsson JSM; La Fleur L; Isaksson J; Jönsson M; Nodin B; Botling J; Uhlén M; Jirström K; Staaf J; Planck M; Brunnström H
    Cancer Med; 2020 Aug; 9(15):5609-5619. PubMed ID: 32491279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer.
    Ehlén Å; Nodin B; Rexhepaj E; Brändstedt J; Uhlén M; Alvarado-Kristensson M; Pontén F; Brennan DJ; Jirström K
    Transl Oncol; 2011 Aug; 4(4):212-21. PubMed ID: 21804916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maspin expression and melanoma progression: a matter of sub-cellular localization.
    Martinoli C; Gandini S; Luise C; Mazzarol G; Confalonieri S; Giuseppe Pelicci P; Testori A; Ferrucci PF
    Mod Pathol; 2014 Mar; 27(3):412-9. PubMed ID: 24030740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of RNA-binding motif protein 3 expression is associated with right-sided localization and poor prognosis in colorectal cancer.
    Melling N; Simon R; Mirlacher M; Izbicki JR; Stahl P; Terracciano LM; Bokemeyer C; Sauter G; Marx AH
    Histopathology; 2016 Jan; 68(2):191-8. PubMed ID: 25922889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma.
    Saldanha G; Joshi K; Lawes K; Bamford M; Moosa F; Teo KW; Pringle JH
    Mod Pathol; 2017 Jan; 30(1):60-68. PubMed ID: 27713424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated expression of minichromosome maintenance 3 indicates poor outcomes and promotes G1/S cell cycle progression, proliferation, migration and invasion in colorectal cancer.
    Zhou H; Xiong Y; Zhang G; Liu Z; Li L; Hou S; Zhou T
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32597491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.
    Kang EY; Millstein J; Popovic G; Meagher NS; Bolithon A; Talhouk A; Chiu DS; Anglesio MS; Leung B; Tang K; Lambie N; Pavanello M; Da-Anoy A; Lambrechts D; Loverix L; Olbrecht S; Bisinotto C; Garcia-Donas J; Ruiz-Llorente S; Yagüe-Fernandez M; Edwards RP; Elishaev E; Olawaiye A; Taylor S; Ataseven B; du Bois A; Harter P; Lester J; Høgdall CK; Armasu SM; Huang Y; Vierkant RA; Wang C; Winham SJ; Heublein S; Kommoss FKF; Cramer DW; Sasamoto N; van-Wagensveld L; Lycke M; Mateoiu C; Joseph J; Pike MC; Odunsi K; Tseng CC; Pearce CL; Bilic S; Conrads TP; Hartmann A; Hein A; Jones ME; Leung Y; Beckmann MW; Ruebner M; Schoemaker MJ; Terry KL; El-Bahrawy MA; Coulson P; Etter JL; LaVigne-Mager K; Andress J; Grube M; Fischer A; Neudeck N; Robertson G; Farrell R; Barlow E; Quinn C; Hettiaratchi A; Casablanca Y; Erber R; Stewart CJR; Tan A; Yu Y; Boros J; Brand AH; Harnett PR; Kennedy CJ; Nevins N; Morgan T; Fasching PA; Vergote I; Swerdlow AJ; Candido Dos Reis FJ; Maxwell GL; Neuhausen SL; Barquin-Garcia A; Modugno F; Moysich KB; Crowe PJ; Hirasawa A; Heitz F; Karlan BY; Goode EL; Sinn P; Horlings HM; Høgdall E; Sundfeldt K; Kommoss S; Staebler A; Wu AH; Cohen PA; DeFazio A; Lee CH; Steed H; Le ND; Gayther SA; Lawrenson K; Pharoah PDP; Konecny G; Cook LS; Ramus SJ; Kelemen LE; Köbel M
    Virchows Arch; 2022 Apr; 480(4):855-871. PubMed ID: 34782936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic and Prognostic Value of Isolated and Combined MCM3 and Glypican-3 Expression in Hepatocellular Carcinoma: A Novel Immunosubtyping Prognostic Model.
    Mohamed AS; Abd El Hafez A; Eltantawy A; Mahfouz M
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):694-702. PubMed ID: 36350065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts.
    Meyer S; Fuchs TJ; Bosserhoff AK; Hofstädter F; Pauer A; Roth V; Buhmann JM; Moll I; Anagnostou N; Brandner JM; Ikenberg K; Moch H; Landthaler M; Vogt T; Wild PJ
    PLoS One; 2012; 7(6):e38222. PubMed ID: 22685558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metallothionein-overexpression as a prognostic factor for progression and survival in melanoma. A prospective study on 520 patients.
    Weinlich G; Bitterlich W; Mayr V; Fritsch PO; Zelger B
    Br J Dermatol; 2003 Sep; 149(3):535-41. PubMed ID: 14510986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple-marker PCR assay of sentinel lymph node as a prognostic factor in melanoma.
    Ito T; Wada M; Nagae K; Nakano-Nakamura M; Nakahara T; Hagihara A; Furue M; Uchi H
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):912-8. PubMed ID: 25199412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
    Kashani-Sabet M; Nosrati M; Miller JR; Sagebiel RW; Leong SPL; Lesniak A; Tong S; Lee SJ; Kirkwood JM
    Clin Cancer Res; 2017 Nov; 23(22):6888-6892. PubMed ID: 28790109
    [No Abstract]   [Full Text] [Related]  

  • 37. Reduced expression of SRY-box containing gene 17 correlates with an unfavorable melanoma patient survival.
    Lu J; Zhang G; Cheng Y; Tang Y; Dong Z; McElwee KJ; Li G
    Oncol Rep; 2014 Dec; 32(6):2571-9. PubMed ID: 25310020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
    Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
    Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma.
    Guo H; Cheng Y; Martinka M; McElwee K
    Oncotarget; 2015 Sep; 6(28):25484-98. PubMed ID: 26329521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioinformatics Analysis Reveals
    Ma H; Liu Z; Li H; Guo X; Guo S; Qu P; Wang Y
    Comput Math Methods Med; 2021; 2021():8494260. PubMed ID: 34671420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.